Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline

Abstract

Eighteen patients received tigecycline as treatment for infection due to multidrug-resistant gram-negative bacilli, including Acinetobacter baumannii and Klebsiella pneumoniae carbapenemase- and extended-spectrum β-lactamase- producing Enterobacteriaceae. Pretherapy minimum inhibitory concentration values for tigecycline predicted clinical success. Observed evolution of resistance during therapy raises concern about routine use of tigecycline in treatment of such infections when other therapies are available. © 2008 by the Infectious Diseases Society of America. All rights reserved.